Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sab Biotherapeutics Inc
(NQ:
SABS
)
2.720
+0.130 (+5.02%)
Streaming Delayed Price
Updated: 3:56 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sab Biotherapeutics Inc
< Previous
1
2
3
4
5
6
Next >
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 18, 2023
Gainers Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional...
Via
Benzinga
Dow Dips Over 100 Points; Bank of America Earnings Beat Estimates
April 18, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 100 points on Tuesday. The Dow traded down 0.42% to 33,842.93 while the NASDAQ fell 0.10% to 12,146.16. The S&P 500,...
Via
Benzinga
Short Volatility Alert: Sab Biotherapeutics
April 18, 2023
On Monday, shares of Sab Biotherapeutics (NASDAQ: SABS) experienced volatile short activity. After the activity, the stock price went up +6.13% to $0.77. The overall sentiment for SABS has been...
Via
Benzinga
SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
April 18, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Secures FDA Breakthrough Therapy Tag For Its Influenza Immunotherapy
April 18, 2023
The FDA has granted Breakthrough Therapy Designation (BTD) to SAB Biotherapeutics Inc's (NASDAQ: SABS) SAB-176, an investigational therapy for post-exposure prophylaxis for Type A and Type B influenza...
Via
Benzinga
Promising Upsides on these Biotech Penny Stocks
April 18, 2023
These three biotech stocks each have a consensus Buy rating. While they are down from historic highs, impressive upsides make them worth consideration.
Via
MarketBeat
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 14, 2023
Via
Benzinga
Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
April 14, 2023
Gainers SAI.TECH Global Corporation (NASDAQ: SAI) jumped 269% to $5.61 after gaining around 25% on Thursday.
Via
Benzinga
Why Navidea Biopharmaceuticals Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
April 14, 2023
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 318% to $29.80 in pre-market trading after gaining more than 345% on Thursday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
April 14, 2023
It's time for another dive into the biggest pre-market stock movers with all the latest news traders need to know about for Friday!
Via
InvestorPlace
Nasdaq Rises 2%; Consolidated Communications Shares Spike Higher
April 13, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Thursday. The Dow traded up 1.09% to 34,013.93 while the NASDAQ rose 2% to 12,167. The S&P 500,...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
April 13, 2023
Via
Benzinga
Dow Rises Over 100 Points; Delta Air Lines Earnings Miss Views
April 13, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Thursday. The Dow traded up 0.43% to 33,790.58 while the NASDAQ rose 1.36% to 12,091.38. The S&P...
Via
Benzinga
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 13, 2023
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday.
Via
Benzinga
Why Is SAB Therapeutics Stock Trading Higher Today?
April 13, 2023
SAB Therapeutics (NASDAQ: SABS) shares are trading higher on Thursday after the company said it has been granted Fast Track designation from the FDA for SAB-176 influenza immunotherapy with high...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 13, 2023
Via
Benzinga
SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza
April 13, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody
April 13, 2023
The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those...
Via
Benzinga
SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
April 04, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Provides Company Update for Full Year 2022
March 31, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
March 29, 2023
On Wednesday, 81 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
March 27, 2023
On Monday, 89 stocks made new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
March 24, 2023
On Friday, 469 companies hit new 52-week lows.
Via
Benzinga
SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference
January 19, 2023
Conference to take place Feb. 6-9 in New York
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract
January 18, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Receives Additional $8.2M In Closeout Of COVID-19 DoD Contract
January 18, 2023
SAB Biotherapeutics (NASDAQ: SABS) has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research and...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 11, 2023
Via
Benzinga
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
January 10, 2023
Study shows SAB’s fully-human polyclonal therapeutic that has potential to delay the onset or progression of type 1 diabetes is well tolerated; next step is investigational new drug (IND) filing
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics' Type 1 Diabetes Candidate Moves One Step Closer To Enter Human Trials With Completion Of Toxicology Study
January 10, 2023
SAB Biotherapeutics (NASDAQ: SABS) has completed an IND-enabling GLP-tox study for SAB-142, further progressing the therapeutic to prevent and/or delay onset and progression of type 1 diabetes (T1D)...
Via
Benzinga
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
January 09, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.